Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
POAI 
Predictive Oncology Inc (POAI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: POAI (1-star) is a SELL. SELL since 3 days. Simulated Profits (-6.59%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.82% | Avg. Invested days 27 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 56.79M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta 1.32 | 52 Weeks Range 9.22 - 33.75 | Updated Date 10/17/2025 |
52 Weeks Range 9.22 - 33.75 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -16.95 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -99174.8% |
Management Effectiveness
Return on Assets (TTM) -87.71% | Return on Equity (TTM) -746.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 12356444 | Price to Sales(TTM) 34.11 |
Enterprise Value 12356444 | Price to Sales(TTM) 34.11 | ||
Enterprise Value to Revenue 7.42 | Enterprise Value to EBITDA -0.51 | Shares Outstanding 762414 | Shares Floating 718973 |
Shares Outstanding 762414 | Shares Floating 718973 | ||
Percent Insiders 0.93 | Percent Institutions 0.24 |
Upturn AI SWOT
Predictive Oncology Inc
Company Overview
History and Background
Predictive Oncology Inc. (formerly Cancer Research Analytics Inc.) was founded in 2000 and has evolved to focus on applying AI and machine learning to drug discovery and personalized medicine. Key milestones include acquisitions of companies specializing in cell-based assays and AI, and the development of the PEDAL platform.
Core Business Areas
- Drug Discovery Services: Provides AI-driven drug discovery and development services to pharmaceutical and biotech companies. This segment uses its proprietary PEDAL platform and cell-based assays to identify promising drug candidates and optimize treatment regimens.
- Research and Development: Focuses on internal research and development efforts to advance its proprietary technologies and develop novel therapeutic approaches for cancer.
Leadership and Structure
The company's leadership team includes a CEO, CFO, and Chief Scientific Officer. The organizational structure is typical of a biotechnology company, with departments dedicated to research, development, sales, and marketing.
Top Products and Market Share
Key Offerings
- PEDAL (Personalized Experience-based Data Analytics Learning) Platform: AI platform used for drug discovery and personalized medicine. Includes cell-based assays and machine learning algorithms. Competitors include companies offering similar AI drug discovery services, such as Schrodinger (SDGR) and Recursion Pharmaceuticals (RXRX).
- Cell-Based Assays: In vitro cancer models used for drug screening and research. Market share information is not readily available. Competitors include companies providing cell-based assay services, such as Charles River Laboratories (CRL) and Eurofins Scientific (ERF).
Market Dynamics
Industry Overview
The pharmaceutical and biotechnology industries are undergoing rapid digital transformation with increasing adoption of AI and machine learning for drug discovery and development. The market is competitive and driven by the need for faster and more efficient drug development processes.
Positioning
Predictive Oncology is positioned as a provider of AI-driven drug discovery solutions and personalized medicine tools. Its competitive advantage lies in its PEDAL platform and cell-based assay technology, although it faces stiff competition from larger, more established players.
Total Addressable Market (TAM)
The TAM for AI in drug discovery is estimated to be in the billions of dollars. Predictive Oncology is positioned to capture a portion of this market through its drug discovery services and personalized medicine offerings.
Upturn SWOT Analysis
Strengths
- Proprietary PEDAL platform
- Expertise in cell-based assays
- Focus on AI and machine learning
- Partnerships with pharmaceutical companies
Weaknesses
- Limited financial resources
- Small market capitalization
- Dependence on partnerships
- Limited product pipeline
Opportunities
- Increasing adoption of AI in drug discovery
- Growing demand for personalized medicine
- Potential for strategic alliances and acquisitions
- Expansion into new therapeutic areas
Threats
- Competition from larger pharmaceutical and biotechnology companies
- Regulatory hurdles
- Technological obsolescence
- Economic downturn
Competitors and Market Share
Key Competitors
- SDGR
- RXRX
- CRL
- ERF
Competitive Landscape
Predictive Oncology's advantages include its proprietary technology and focused approach. Disadvantages include its small size and limited resources compared to larger competitors.
Major Acquisitions
Skyline Medical Inc
- Year: 2020
- Acquisition Price (USD millions): 0
- Strategic Rationale: To expand their product offerings and market reach, even though the acquisition was related to non-cancer medical disposal systems which was eventually divested
Growth Trajectory and Initiatives
Historical Growth: Historical growth data requires access to real-time financial databases. Recent financial reports should be consulted. This section will be left blank as it requires live market data.
Future Projections: Future projections require access to analyst estimates. This section will be left blank as it requires live market data.
Recent Initiatives: Recent initiatives include expanding the capabilities of the PEDAL platform, forming partnerships with pharmaceutical companies, and advancing internal research programs.
Summary
Predictive Oncology focuses on AI-driven drug discovery. Its PEDAL platform and cell-based assays are key assets. Financial constraints and strong competition present challenges. Strategic partnerships and innovation are critical for growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data is approximate. Actual results may vary. Data is provided as of October 26, 2023.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Predictive Oncology Inc
Exchange NASDAQ | Headquaters Pittsburgh, PA, United States | ||
IPO Launch date 2018-01-29 | CEO & Chairman Mr. Raymond F. Vennare | ||
Sector Healthcare | Industry Health Information Services | Full time employees 23 | Website https://predictive-oncology.com |
Full time employees 23 | Website https://predictive-oncology.com | ||
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of cancer therapies. It operates through two segments, Pittsburgh and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. This segment also creates proprietary 3D culture models used in drug development. Its Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. Predictive Oncology Inc. has a strategic collaboration with Every Cure to identify and prioritize drugs for repurposing. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Pittsburgh, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.